CompletedPhase 1NCT00003217
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Timothy C. Griffin, MD, MDCook Children's Medical Center - Fort Worth
- Intervention
- filgrastim(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 1998 – 2006
Study locations (14)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
- Children's Memorial Hospital, Chicago, Chicago, Illinois, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- University of Rochester Cancer Center, Rochester, New York, United States
- State University of New York - Upstate Medical University, Syracuse, New York, United States
- Oklahoma Memorial Hospital, Oklahoma City, Oklahoma, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Simmons Cancer Center - Dallas, Dallas, Texas, United States
- Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
- Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States
- Alberta Children's Hospital, Calgary, Alberta, Canada
- Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003217 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital